US Patent No: 4,844,910

Number of patents in Portfolio can not be more than 2000

Spheroids

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

A controlled release pharmaceutical composition comprising a plurality of film coated spheroids, the film coated spheroids comprising a 3-alkylxanthine, a non-water soluble spheronising agent and between 4% and 9% (by weight) water, wherein the in-vitro dissolution rate of the 3-alkylxanthine from the film coated spheroids, when measured by the USP Paddle Method at 100 rpm in 900 ml aqueous buffer (pH 6.5 at 37.degree. C.) is between 7.5% and 25.0% (by wt) release after 1 hour, between 22.5% and 45.0% (by wt) release after 2 hours, between 40.0% and 60.0% (by wt) release after 3 hours, between 50.0% and 75.0% (by wt) release after 4 hours, between 70.0% and 92.5% (by wt) release after 6 hours, and between 80.0% and 100.0% (by wt) release after 8 hours. Preferably the water content is between 4% and 8%, especially between 4% and 7% (by wt) of the film coated spheroid formulation. The preferred 3-alkylxanthine is theophylline (anhydrous or hydrate), whilst the preferred spheronising agent is microcrystalline cellulose.

Loading the Abstract Image... loading....

First Claim

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
EURO-CELTIQUE S.A.LUXEMBOURG164
EUROCELTIQUE S.A., 122, BOULEVARD DE LA PETRUSSE, LUXEMBOURGSTAMFORD, CT5

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Leslie, Stewart T Cambridge, GB2 24 1262
Malkowska, Sandra T A Cambridgeshire, GB2 17 1090
Marchant, Joanne St. Ives, GB3 2 44
Neale, Philip J Cambridge, GB 7 586

Cited Art Landscape

Patent Info (Count) # Cites Year
 
EGYT GYOGYSZERVEGYESZETI GYAR, 30-38, KERESZTURI UT, H-1106 BUDAPEST, HUNGARY (1)
4,748,023 Process for the preparation of sustained release pharmaceutical compositions having a high active ingredient content 38 1984
 
Key Pharmaceuticals, Inc. (1)
4,587,118 Dry sustained release theophylline oral formulation 46 1984

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
PURDUE PHARMA L.P. (20)
6,696,088 Tamper-resistant oral opioid agonist formulations 66 2001
7,943,173 Pharmaceutical combinations of oxycodone and naloxone 2 2002
7,914,818 Opioid agonist formulations with releasable and sequestered antagonist 4 2002
6,696,066 Opioid agonist/antagonist combinations 54 2002
7,842,311 Tamper-resistant oral opioid agonist formulations 4 2003
7,172,767 Opioid agonist / antagonist combinations 27 2003
7,842,309 Tamper-resistant oral opioid agonist formulations 3 2003
7,718,192 Tamper-resistant oral opioid agonist formulations 10 2003
7,682,632 Tamper-resistant oral opioid agonist formulations 10 2003
7,658,939 Tamper-resistant oral opioid agonist formulations 12 2003
7,384,653 Oral dosage form comprising a therapeutic agent and an adverse-effect agent 12 2004
8,465,774 Sequestered antagonist formulations 0 2006
7,419,686 Opioid agonist/antagonist combinations 14 2006
7,749,542 Opioid agonist/antagonist combinations 2 2008
8,105,631 Opioid agonist/antagonist combinations 1 2010
8,236,351 Tamper-resistant oral opioid agonist formulations 0 2010
8,231,901 Opioid agonist formulations with releasable and sequestered antagonist 0 2011
8,518,443 Opioid agonist formulations with releasable and sequestered antagonist 0 2012
8,357,399 Tamper-resistant oral opioid agonist formulations 0 2012
8,586,088 Tamper-resistant oral opioid agonist formulations 0 2012
 
ALPHARMA PHARMACEUTICALS, LLC (4)
8,158,156 Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist 0 2007
8,623,418 Pharmaceutical composition 0 2008
7,682,633 Pharmaceutical composition 1 2009
7,682,634 Pharmaceutical compositions 1 2009
 
ELITE LABORATORIES INC. (2)
8,182,836 Abuse-resistant oral dosage forms and method of use thereof 0 2009
8,425,933 Abuse-resistant oral dosage forms and method of use thereof 0 2009
 
EURO-CELTIQUE S.A. (2)
5,091,189 Controlled release dosage forms having a defined water content 30 1991
8,518,925 Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) 0 2005
 
IPSEN PHARMA S.A.S. (2)
5,213,812 Preparation process of sustained release compositions and the compositions thus obtained 20 1991
5,569,467 Process for the preparation of microballs and microballs thus obtained 14 1994
 
ABBOTT LABORATORIES (1)
5,160,742 System for delivering an active substance for sustained release 32 1991
 
American Cyanamid Company (1)
5,283,065 Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form 74 1992
 
F.H. FAULDING & CO. LIMITED (1)
5,196,203 Theophylline dosage form 41 1991
 
NORDMARK ARZNEIMITTEL GMBH & CO. KG (1)
5,160,469 Manufacture of pellets of xanthine derivatives 2 1990
 
PHILIP MORRIS USA INC. (1)
7,866,324 Cigarette and filter with cellulosic flavor addition 0 2006
 
ROCHE DIAGNOSTICS OPERATIONS, INC. (1)
5,413,690 Potentiometric biosensor and the method of its use 265 1993
 
TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (1)
5,945,125 Controlled release tablet 37 1996
 
WYETH HOLDINGS LLC (1)
5,776,489 Controlled release carbonic anhydrase inhibitor containing pharmaceutical compositions from spherical granules in capsule oral dosage unit form 10 1992